

6. *Request for Reconsideration*—20 CFR 404.907–404.921, 416.1407–416.1421, 408.1009, and 418.1325—0960–0622. The Social Security Act states those individuals who are dissatisfied with the results of an initial determination regarding their Title II disability; Title XVI disability (SSI); Title VIII (Special Veterans benefits); or Title XVIII (Medicare benefits), can request a reconsideration hearing.

Individuals use Form SSA–561–U2; the associated MCS or SSI Claims System interview; or the internet application (i561) to initiate a request for reconsideration of a denied claim. SSA uses the information to document the request and to determine an individual’s eligibility or entitlement to Social Security benefits (Title II); SSI payments (Title XVI); Special Veterans Benefits (Title VIII); Medicare (Title XVIII); and

for initial determinations regarding Medicare Part B income-related premium subsidy reductions. The respondents are applicants, claimants, beneficiaries, or recipients filing for reconsideration of an initial determination.

Type of Request: Revision of an OMB-approved information collection.

Modality of completion	Number of respondents	Frequency of response	Average burden per response (minutes)	Estimated total annual burden (hours)	Average theoretical hourly cost amount (dollars)*	Average wait time in field office (minutes)**	Total annual opportunity cost (dollars)***
SSA–561, MCS, SSI Claims System	339,217	1	8	45,229	*\$31.48	**23	***\$5,517,248
i561 (Internet iAppeals)	447,139	1	15	111,785	*31.48	*** 3,518,992
Total	786,356	157,014	***9,036,240

* We based this figure on average U.S. worker’s hourly wages, as reported by Bureau of Labor Statistics data (https://www.bls.gov/oes/current/oes_nat.htm).
 ** We based this figure on the average FY 2025 wait times for field offices, based on SSA’s current management information data.
 *** This figure does not represent actual costs that SSA is imposing on recipients of Social Security payments to complete this application; rather, these are theoretical opportunity costs for the additional time respondents will spend to complete the application. *There is no actual charge to respondents to complete the application.*

Tasha Harley,
Acting Reports Clearance Officer, Social Security Administration.
 [FR Doc. 2025–03847 Filed 3–10–25; 8:45 am]
BILLING CODE 4191–02–P

DEPARTMENT OF THE TREASURY
Office of Foreign Assets Control
Notice of OFAC Sanctions Action
AGENCY: Office of Foreign Assets Control, Treasury.
ACTION: Notice.
SUMMARY: The U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) published the name of

one individual and one entity that has been placed on OFAC’s Specially Designated Nationals and Blocked Persons List (SDN List) based on OFAC’s determination that one or more applicable legal criteria were satisfied. All property and interests in property subject to U.S. jurisdiction of this individual and entity are blocked, and U.S. persons are generally prohibited from engaging in transactions with this individual and entity.
DATES: This action was issued on March 5, 2025. See **SUPPLEMENTARY INFORMATION** for relevant dates.
FOR FURTHER INFORMATION CONTACT: OFAC: Associate Director for Global Targeting, 202–622–2420; Assistant

Director for Sanctions Compliance, 202–622–2490 or <https://ofac.treasury.gov/contact-ofac>.
SUPPLEMENTARY INFORMATION:
Electronic Availability
 The SDN List and additional information concerning OFAC sanctions programs are available on OFAC’s website: <https://ofac.treasury.gov>.
Notice of OFAC Action
 On March 5, 2025, OFAC determined that the property and interests in property subject to U.S. jurisdiction of the following individual and entity are blocked under the relevant sanctions authority listed below.
BILLING CODE 4810–AL–P

Individual

1. ZHOU, Shuai (Chinese Simplified: 周帅), Room 301, No. 62, Lane 287, Gulong Road, Minhang District, Shanghai 201102, China; DOB 09 Jul 1979; POB Dongtai, China; nationality China; Gender Male; Passport E82979246 (China) expires 17 Jul 2026; National ID No. 320981197907090475 (China) (individual) [CYBER3] (Linked To: SHANGHAI HEIYING INFORMATION TECHNOLOGY COMPANY, LIMITED).

Designated pursuant to section 1(a)(iii)(B) of Executive Order 13694 of April 1, 2015, "Blocking the Property of Certain Persons Engaging in Significant Malicious Cyber-Enabled Activities," 80 FR 18077, 3 CFR, 2015 Comp., p. 297, as amended by Executive Order 13757 of December 28, 2016, "Taking Additional Steps to Address the National Emergency With Respect to Significant Malicious Cyber-Enabled Activities," 82 FR 1, 3 CFR, 2016 Comp., p. 659, and as further amended by Executive Order 14144 of January 16, 2025, "Strengthening and Promoting Innovation in the Nation's Cybersecurity," 90 FR 6755 ("E.O. 13694, as further amended"), for being responsible for or complicit in, or having engaged in, directly or indirectly, activities related to gaining or attempting to gain unauthorized access to a computer or network of computers of a United States person, the United States, a United States ally or partner or a citizen, national, or entity organized under the laws thereof, where such efforts originate from or are directed by persons located, in whole or substantial part, outside the United States and are reasonably likely to result in, or have materially contributed to, a

significant threat to the national security, foreign policy, or economic health or financial stability of the United States.

2. SHANGHAI HEIYING INFORMATION TECHNOLOGY COMPANY, LIMITED (Chinese Simplified: 上海黑英信息技术有限公司), Room J2518, No. 912, Yecheng Road, Jiading Industrial District, Shanghai 201800, China; Organization Established Date 07 Jun 2010; Organization Type: Other information technology and computer service activities; Registration Number 310114002134793 (China); Unified Social Credit Code (USCC) 913101145559933417 (China) [CYBER3] (Linked To: ZHOU, Shuai).

Designated pursuant to section 1(a)(iii)(D) of Executive Order 13694, as further amended, for being owned or controlled by, or having acted or purported to act for or on behalf of, directly or indirectly, any person whose property and interests in property are blocked pursuant to E.O. 13694, as further amended, or that has engaged in any activity describer in subsections (a)(ii) or (a)(iii)(A)–(C) of section 1 of E.O. 13694, as further amended.

Lisa M. Palluconi,
Acting Director, Office of Foreign Assets Control.

[FR Doc. 2025–03819 Filed 3–10–25; 8:45 am]

BILLING CODE 4810–AL–C

DEPARTMENT OF VETERANS AFFAIRS

Tiered Pharmacy Copayments for Medications; Calendar Year 2025 Update

AGENCY: Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: This Department of Veterans Affairs (VA) notice updates the information on Tier 1 medications.

FOR FURTHER INFORMATION CONTACT: Tamara Wagner, Management Analyst, Office of Finance/Revenue Operations, Veterans Health Administration, Department of Veterans Affairs, 128 Bingham Road, Suite 1000, Asheville, NC 28806; telephone 970–242–0731, extension 2219. (This is not a toll-free telephone number.)

SUPPLEMENTARY INFORMATION: Section 17.110 of title 38, Code of Federal Regulations (CFR), governs copayments for medications that VA provides to veterans. Section 17.110 provides the methodologies for establishing the copayment amount for each 30-day or less supply of medication provided by VA on an outpatient basis (other than medication administered during treatment).

Tier 1 medication means a multi-source medication that has been

identified using the process described in 38 CFR 17.110(b)(1)(iv)(A)(1)(i) and (ii). Not less than once per year, VA will identify a subset of multi-source medications as Tier 1 medications. Only medications that meet all the criteria in 38 CFR 17.110(b)(2)(i), (ii), and (iii) will be eligible to be considered Tier 1 medications, and only those medications that meet all the criteria in 38 CFR 17.110(b)(2)(i) will be assessed using the criteria in paragraphs (b)(2)(ii) and (iii).

Based on the methodologies set forth in § 17.110, this notice updates the list of Tier 1 medications for Calendar Year 2025. The Tier 1 medication list is posted on VA’s website at the following link: <https://www.va.gov/resources/va-tier-1-copay-medication-list/>.

The following table is the Tier 1 Copay Medication List that is effective

January 1, 2025, and will remain in effect until December 31, 2025.

Condition	VA product name
Arthritis and Pain	Aspirin buffered tablet, Aspirin chewable tablet, Aspirin enteric coated tablet, Allopurinol tablet, Celecoxib capsule, Diclofenac tablet, Ibuprofen tablet, Meloxicam tablet, Naproxen tablet.
Blood Thinners and Platelet Inhibitors.	Clopidogrel Bisulfate tablet.
Cholesterol	Atorvastatin tablet, Ezetimibe tablet, Fenofibrate capsule or tablet, Pravastatin tablet, Rosuvastatin Calcium (CA) tablet, Simvastatin tablet.
Dementia	Donepezil tablet.
Diabetes	Glipizide tablet, Metformin Hydrochloride HCL tablet, Metformin HCL 24-hour Sustained Action (SA) tablet, Pioglitazone HCL tablet.
Electrolyte Supplement	Potassium SA tablet, Potassium SA dispersible tablet.
Gastrointestinal Health	Famotidine tablet, Omeprazole Enteric-Coated (EC) capsule, Pantoprazole Sodium capsule.
Glaucoma and Eye Care	Carboxymethylcellulose Sodium solution, Diclofenac solution, Latanoprost 0.005% solution, Polyethylene Glycol Solution.